+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07792954

Evaluation of Once-Weekly Berobenatide Injection Compared to Placebo in Chinese Adults With Overweight or Obesity

Led by Pfizer · Updated on 2026-10-15

300

Participants Needed

34

Research Sites

10 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying berobenatide to evaluate its safety and effectiveness in adults in China who have overweight or obesity. This study compares berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. Participants may include adults with obesity or those with overweight and certain weight-related health conditions, some of whom may also have type 2 diabetes. Participants will be randomly assigned to receive either berobenatide or placebo once weekly. Those receiving berobenatide will go through a dose-escalation phase followed by a maintenance phase with low, medium, or high doses. The placebo group will receive matching injections once weekly throughout both phases. The study will carefully monitor treatment effects and changes during these periods. During the study, participants will attend visits and complete assessments to track body weight, overall health, and safety. Researchers will collect data on many health measures, including body weight changes, waist size, blood pressure, cholesterol, blood sugar levels, and quality of life. Safety monitoring will continue up to 58 weeks. The main outcome is the percent change in body weight from baseline to week 48, with additional health and safety measures also evaluated.

CONDITIONS

Brief Title

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here